Current News

Print version | PDF version | Send article | RSS-Feed

Gambro and Nephrogen - new partner for regenerative medicine program

25 Oct 2005 - Gambro has recently signed an agreement with Nephrogen, LLC as part of its Regenerative Medicine initiative announced earlier this year. The program will extend over a period of three years with the target to restore the function of the kidney using adult stem cells. Initial research will focus on the indication of acute renal failure.
 
In February 2005, Gambro announced that it would invest around MSEK 100 over three years in the field of regenerative medicine. The funds will be used for internal research as well as to support outside collaborators such as Nephrogen. The next three years funds will finance cell selection and expansion technology and clinical trials. Gambro will primarily focus on developing new tools for cell handling and processing, while Nephrogen will contribute with scientific and clinical expertise. The objective with the current program is to publish first clinical results in two to three years.